RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:300857

T-cell/histiocyte rich large B cell lymphoma

low confidenceDisorder

Also known as: THRLBCL

Publications

591

Trials

16

Interventional, condition-specific

Researchers

1,434

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

T-cell/histiocyte rich large B cell lymphoma (THRLBCL) is a rare variant of diffuse large B-cell lymphoma (DLBCL), mainly affecting middle-aged men and often not being discovered until an advanced disease stage, with involvement of the spleen, liver and bone marrow occurring at a greater frequency than in DLBCL. It is often difficult to diagnose due to its similarity with other lymphoid diseases such as classic Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma and has an aggressive clinical course.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (3)

T-cell rich/histiocyte-rich large B-cell lymphoma · T-cell/histiocyte rich lymphoma · T-cell/histiocyte-rich large B-cell lymphoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    591 matched papers (435 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    16 matched on ClinicalTrials.gov (8 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

591

591 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

591 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

435 in the last 10 years · low confidence

Phrase hits: 591 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,434

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Hartmann S9 papers · 2025

    Dr. Senckenberg Institute of Pathology, Goethe University, Frankfurt am Main, Germany.

    Papers in Europe PMC
  2. 02
    Nakamura S7 papers · 2023

    Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan.

    Papers in Europe PMC
  3. 03
    Fromm JR6 papers · 2025

    Department of Laboratory Medicine, University of Washington, Seattle, Washington.

    Papers in Europe PMC
  4. 04
    Jaffe ES6 papers · 2025

    Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD.

    Papers in Europe PMC
  5. 05
    de Leval L5 papers · 2026

    Department of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland.

    Papers in Europe PMC
  6. 06
    Hansmann ML5 papers · 2025

    Dr Senckenberg Institute of Pathology, Goethe University, 60590 Frankfurt am Main, Germany.

    Papers in Europe PMC
  7. 07
    Salles G5 papers · 2025

    Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

    Papers in Europe PMC
  8. 08
    Satou A5 papers · 2023

    Department of Surgical Pathology, Aichi Medical University, Nagakute 480-1195, Japan.

    Papers in Europe PMC
  9. 09
    Takahara T5 papers · 2023

    Department of Surgical Pathology, Aichi Medical University, Nagakute 480-1195, Japan.

    Papers in Europe PMC
  10. 10
    Tousseyn T5 papers · 2025

    Department of Pathology, Universitair Ziekenhuis Leuven Hospitals, Leuven, Belgium.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

16

interventional trials for this specific condition

16 interventional trials matched this specific condition name; 8 currently recruiting in our sample.

Data as of 27 July 2026

16 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 93.7th percentile).

low confidence · 93.7th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

16 interventional trials matched after quoted-phrase search and title/condition post-filter.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"T-cell/histiocyte rich large B cell lymphoma" OR "THRLBCL" OR "T-cell rich/histiocyte-rich large B-cell lymphoma" OR "T-cell/histiocyte rich lymphoma" OR "T-cell/histiocyte-rich large B-cell lymphoma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"T-cell/histiocyte rich large B cell lymphoma" OR "THRLBCL" OR "T-cell rich/histiocyte-rich large B-cell lymphoma" OR "T-cell/histiocyte rich lymphoma" OR "T-cell/histiocyte-rich large B-cell lymphoma"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 16 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (591) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-27T12:44:06.530Z